Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era

• Verfasst von: Hübel, Kai [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Titel: Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era
• Titelzusatz: a retrospective study by the EBMT Lymphoma Working Party
• Verf.angabe: Kai Hübel, Alessandro Re, Ariane Boumendil, Herve Finel, Marcus Hentrich, Stephen Robinson, Christoph Wyen, Mariagrazia Michieli, Edward Kanfer, Jose Luis Diez-Martin, Pascual Balsalobre, Laure Vincent, Wilfried Schroyens, Josep Maria Ribera Santasusana, Nicolaus Kröger, Xaver Schiel, Kate Cwynarski, Albert Esquirol, Aida Botelho Sousa, Chiara Cattaneo, Silvia Montoto, Peter Dreger
• E-Jahr: 2019
• Jahr: 25 February 2019
• Umfang: 7 S.
• Fussnoten: Gesehen am 29.10.2019
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2019
• Band/Heft Quelle: 54(2019), 10, Seite 1625-1631
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/s41409-019-0480-x
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1680631403

Abstract

The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24-66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.